|
HLA-DPB1*0401/0402-positive
patients with epithelial ovarian cancer evaluated in this study.
|
Patients
|
Clinical
|
NY-ESO-1
|
ELISPOT
assays c
|
|
No.
a
|
Age
|
Stage
|
Response
|
Recurrence
|
Follow-up
(mo)
|
Status
b
|
IHC
|
RT-PCR
|
ELISA
|
IFN-gamma
|
IL-5
|
|
NY-ESO-1
Ab-positive/HLA-DP4-positive patients
|
|
1
|
75
|
IV
|
PR
|
persistent
disease
|
40
|
AWD
|
+++
|
+
|
+
|
+
|
+
|
|
2
|
60
|
IIIc
|
CR
|
yes
|
45
|
AWD
|
+
|
+
|
+
|
+
|
+
|
|
3
|
66
|
IIIc
|
CR
|
yes
|
40
|
DOD
|
+++
|
+
|
+
|
+
|
-
|
|
4
|
58
|
IIIc
|
CR
|
no
|
47
|
ANED
|
-
|
+
|
+
|
+
|
+
|
|
5
|
58
|
IIIc
|
CR
|
no
|
51
|
ANED
|
+++
|
NA
|
+
|
-
|
-
|
|
6
|
43
|
IIIc
|
CR
|
no
|
13
|
ANED
|
+
|
-
|
+
|
-
|
-
|
|
18
|
75
|
III
|
CR
|
no
|
6
|
ANED
|
++
|
+
|
+
|
+
|
-
|
|
25
|
91
|
IIIc
|
PR
|
yes
|
7
|
AWD
|
NA
|
-/+
d
|
+
|
+
|
+
|
|
27
|
39
|
NA
|
CR
|
yes
|
18
|
DOD
|
+
|
NA
|
+
|
-
|
-
|
|
28
|
39
|
3
|
PR
|
yes
|
39
|
AWD
|
+
|
NA
|
+
|
+
|
+
|
|
29
|
76
|
IIIc
|
CR
|
yes
|
99
|
AWD
|
+
|
NA
|
+
|
-
|
-
|
|
30
|
21
|
IIIb
|
PR
|
yes
|
18
|
DOD
|
+
|
NA
|
+
|
-
|
-
|
|
NY-ESO-1
Ab-negative/HLA-DP4-positive patients
|
|
7
|
47
|
IIIc
|
NA
|
NA
|
11
|
ANED
|
-
|
-/+
d
|
-
|
+
|
-
|
|
8
|
51
|
IIIc
|
PR
|
persistent
disease
|
51
|
ANED
|
+++
|
NA
|
-
|
-
|
-
|
|
9
|
53
|
IV
|
CR
|
yes
|
36
|
AWD
|
+
|
-
|
-
|
-
|
-
|
|
10
|
52
|
IIIc
|
CR
|
yes
|
26
|
AWD
|
+
|
-
|
-
|
-
|
-
|
|
11
|
62
|
IIIc
|
CR
|
no
|
9
|
ANED
|
-
|
-/+
d
|
-
|
-
|
-
|
|
12
|
75
|
IIIc
|
CR
|
yes
|
74
|
ANED
|
+
|
+
|
-
|
-
|
-
|
|
13
|
70
|
IIIc
|
CR
|
yes
|
37
|
AWD
|
+
|
-
|
-
|
-
|
-
|
|
19
|
75
|
IIIc
|
CR
|
no
|
78
|
ANED
|
+
|
NA
|
-
|
-
|
-
|
|
20
|
73
|
III
|
CR
|
yes
|
15
|
AWD
|
-
|
+
|
-
|
-
|
-
|
|
21
|
41
|
IIIc
|
CR
|
yes
|
13
|
ANED
|
-
|
-/+
d
|
-
|
-
|
-
|
|
22
|
51
|
IIIc
|
NA
|
NA
|
3
|
AWD
|
+
|
+
|
-
|
-
|
-
|
|
23
|
48
|
IIIc
|
CR
|
yes
|
106
|
ANED
|
++
|
+
|
-
|
+
|
+
|
|
24
|
79
|
IIIc
|
CR
|
NA
|
8
|
ANED
|
+++
|
-
|
-
|
+
|
-
|
|
26
|
57
|
IIIc
|
NA
|
NA
|
5
|
AWD
|
NA
|
+
|
-
|
-
|
-
|
|
NY-ESO-1
Ab-positive/HLA-DP4-negative patients
|
|
14
|
72
|
II
|
CR
|
no
|
3
|
AWD
|
++++
|
-
|
+
|
-
|
-
|
|
15
|
66
|
IIIc
|
CR
|
yes
|
33
|
ANED
|
+++
|
NA
|
+
|
-
|
-
|
|
Healthy
donors
|
|
16
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
-
|
-
|
|
17
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
-
|
-
|
aAll
patients had EOC, except for 27 (schwannoma), 28 (melanoma), and
16 and 17 (healthy donors).
bAbbreviations: AWD, alive with disease; ANED, alive
with no evidence of disease; DOD, die of disease; NA, not available.
cResults are representative of at least two separate
reproducible ELISPOT assays.
dThese patients were NY-ESO-1 negative and LAGE-1
positive by RT-PCR.
|
